Download Gene Section MYCN (myc myelocytomatosis viral related oncogene, neuroblastoma derived)

Atlas of Genetics and Cytogenetics
in Oncology and Haematology
OPEN ACCESS JOURNAL AT INIST-CNRS
Gene Section
Mini Review
MYCN (myc myelocytomatosis viral related
oncogene, neuroblastoma derived)
Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Published in Atlas Database: March 1998
Online updated version: http://AtlasGeneticsOncology.org/Genes/NMYC112.html
DOI: 10.4267/2042/37407
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 1998 Atlas of Genetics and Cytogenetics in Oncology and Haematology
Identity
MYCN (2p24) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. Laboratories willing to validate the probes are
welcome: contact [email protected].
Location: 2p24.1
C-term; forms heterodimers with MAX and recognize
the core concensus sequence CACCTG.
Local order: centromeric to DDX1
DNA/RNA
Expression
Description
Localisation
3 exons.
Nuclear.
Protein
Function
Description
Probable transcription factor; possible role during
tissue differentiation.
464 amino acids; contains a phosphorylation site, an
acidic domain, an HLH motif, and a leucine zipper in
Homology
Atlas Genet Cytogenet Oncol Haematol. 1998;2(2)
During fetal development.
With members of the myc family of helix-loop-helix
transcription factors.
41
MYCN (myc myelocytomatosis viral related oncogene, neuroblastoma derived)
Huret JL
high lactate dehydrogenase, ferritin, and neuronspecific enolase serum levels).
Mutations
Somatic
References
Amplification, either in extrachromosomal double
minutes or in homogeneously staining regions within
chromosomes (there is amplification when, for
exemple, 10 to 1000 copies of a gene are present in a
cell); found amplified in a variety of human tumours, in
particular in and also in retinoblastoma, small cell lung
carcinoma, astrocytoma; level of amplification related
to the tumour progression; transgenic mice that
overexpress MYCN in neuroectodermal cells develop
neuroblastoma.
Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F,
Alt FW. Transposition and amplification of oncogene-related
sequences in human neuroblastomas. Cell 1983 Dec;35(2 Pt
1):359-67.
Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G,
Cordero di Montezemolo L, Casale F, Pession A, Perri P,
Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N,
Milanaccio C, Conte M, Bruzzi P, De Bernardi B. MYCN
oncogene amplification in neuroblastoma is associated with
worse prognosis, except in stage 4s: the Italian experience
with 295 children. J Clin Oncol 1997 Jan;15(1):85-93.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop
JM. Targeted expression of MYCN causes neuroblastoma in
transgenic mice. EMBO J 1997 Jun 2;16(11):2985-95.
Implicated in
Neuroblastoma
This article should be referenced as such:
Oncogenesis
MYCN amplification is found in 15% of
neuroblastoma, is an adverse prognostic feature per se,
and is often associated with other adverse features
(older age, abdominal tumour, advanced disease, and
Atlas Genet Cytogenet Oncol Haematol. 1998;2(2)
Huret JL. MYCN (myc myelocytomatosis viral related
oncogene, neuroblastoma derived). Atlas Genet Cytogenet
Oncol Haematol.1998;2(2):41-42.
42